Expression of Concern: Amino acid management of parkinson’s disease: A case study (Int J Gen Med., (2011) 4, (165–174), 10.2147/IJGM.S16621);Amino acid management of Parkinson's disease: A case study

International Journal of General Medicine

Volumn 4, Issue , 2011, Pages 165-174

  Hinz, Marty ^a   Stein, Alvin ^b   Uncini, Thomas ^c  

^a NeuroResearch Clinics Inc   (United States)

^b Stein Orthopedic Associates   (United States)

^c DBS Labs   (United States)

Author keywords

5 HTP; L dopa; Parkinson's; Parkinson's disease; Parkinsonism

Indexed keywords

5 HYDROXYTRYPTOPHAN; CARBIDOPA; CYSTEINE; DOPAMINE; GLUTATHIONE; LEVODOPA; SEROTONIN; TRYPTOPHAN; TYROSINE;

ADULT; ARTICLE; CASE REPORT; CASE STUDY; CATECHOLAMINE URINE LEVEL; DOSE RESPONSE; DRUG DOSE TITRATION; HUMAN; NAUSEA; PARKINSON DISEASE; PATIENT ASSESSMENT; PROTEIN DEPLETION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR;

EID: 84897366608     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S240091     Document Type: Erratum

References (38)

1. Barbeau A. L-Dopa therapy in Parkinson's disease: A critical review of nine years' experience. Can Med Assoc J. 1969;101(13): 59-68.
2. Peaston M, Bis-Nchine J. Metabolic studies and clinical observations during L-Dopa treatment of Parkinson's disease. BMJ. 1970;1: 400-403.
3. FDA-approved carbidopa/levodopa prescribing information. Available from: http://packageinserts.bms.com/pi/pi_sinemet_cr.pdf. Accessed January 20, 2011.
4. FDA-approved ropinirole prescribing information. Available from: http://us.gsk.com/products/assets/us_requip.pdf. Accessed January 20, 2011.
5. FDA-approved amantadine prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf. Accessed January 20, 2011.
6. FDA-approved trihexylphenidyl prescribing information. Available from: http://www.drugs.com/pro/trihexyphenidyl.html. Accessed January 20, 2011.
7. FDA-approved rasagiline mesylate prescribing information. Available from: http://www.drugs.com/monograph/rasagiline-mesylate.html. Accessed January 20, 2011.
8. FDA-approved entacapone prescribing information. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf. Accessed January 20, 2011.
9. Mayo Clinic Parkinson's disease. Available from: http://www.mayoclinic.com/health/parkinsons-disease/DS00295/DSECTION=treatments-and-drugs. Accessed January 20, 2011.
10. Hinz M. Depression. In: Kohlstadt I, editor. Food and Nutrients in Disease Management. Baton Rouge, FL: CRC Press; 2009: 465-481.
11. Hinz M, Stein A, Uncini T. The dual-gate lumen model of renal monoamine transport. Neuropsychiatr Dis Treat. 2010;6:387-392.
12. Hinz M, Stein A, Trachte G, Uncini T. Neurotransmitter testing of the urine, a comprehensive analysis. Open Access Journal of Urology. 2010;2:177-183.
13. Hinz M, Stein A, Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole. Neuropsychiatr Dis Treat. 2010;6:741-747.
14. Stein A, Hinz M, Uncini T. Amino acid responsive Crohn's disease: a case study. Clinical & Experimental Gastroenterology. 2010;3: 171-177.
15. Charlton C, Crowell B, Parkinson's disease-like effects of S-adenosyl- L-methionine: Effects of l-dopa. Pharmacolo Biochem Behav. 1992; 43:423-431.
16. Mones R, Elizan T, Siegel G. Analysis of l-dopa induced dyskenesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971;34:668-673.
17. Charlton C. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosyl methionine: A model that may explain the occurrence of depression in Parkinson's disease. Life Sci. 1997;61(5): 495-502.
18. Karobath M, Diaz J Huttunen M. The effect of l-dopa on the concentrations of tryptophan, tyrosine, and serotonin in the rat brain. Eur J Pharmacol. 1971;14:393-396.
19. Zhelyaskov D, Levitt M, Udenfriend S. Tryptophan derivatives as inhibitors of tyrosine hydroxylase in vivo and vitro. Mol Pharmacol. 1968;4:445-451.
20. Garcia N, Berndt T, Tyce G, Knox F. Chronic oral L-DOPA increases dopamine and decreases serotonin excretions. Am J Physiol. 1999;277 (5 Pt 2):R1476-R1480.
21. Ng K, Chase T, Colburn R, Kopin I. L-Dopa induced release of cerebral monoamines. Science. 1970;170:76-77.
22. Borah A, Kochupurackal P, Mohanakumar P. Long-term l-dopa treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol. 2007;27:985-996.
23. Soares-da-Silva P, Pinto-do-O P. Antagonistic actions of renal dopamine and 5-hydroxytryptamine: effects of amine precursors on the cell inward transfer and decarboxylation Br J Pharmacol. 1996;117: 1187-1192.
24. Wuerthele S, Moore K. Studies of the mechanisms of l-dopa induced depletion of 5-hydroxytryptamine in the mouse brain. Life Sci. 1977; 20:1675-1680.
25. Zeevalk G, Manzino L, Sonsalla PK, Bernard LP. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease. Exp Neurol. 2007;203:512-520.
26. Ritvo E, Yuwiler A, Geller E. Effects of l-dopa in autism. J Autism Dev Disord. 1971;1(2).
27. Benson R, Crowell B, Hill B. The effects of L-Dopa on the activity of methionine adenosyltransferase: Relevance to L-Dopa therapy and tolerance. Neurochemical Res.1993;18(3):325-330.
28. Liu X, Wilson K, Charlton C. Effects of l-dopa treatment on methylation in mouse brain: Implications for side effects of l-dopa. Life Sci. 2000;66(23):2277-2288.
29. Fuller R, Hemrick-Luecke S, Perry K. Effects of l-dopa on epinephrine concentration in rat brain: Possible role of inhibition of norepinephrine N-methyl transferase by S-adenosyl homocysteine. J Pharmacol Exp Ther. 1982;223(1):84-89.
30. FDA-approved carbidopa/l-dopa prescribing information. Available from: http://packageinserts.bms.com/pi/pi_sinemet_cr.pdf. Accessed January 19, 2011.
31. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: A double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75:1672-1677.
32. Trachte G, Uncini T, Hinz M. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat. 2009;5:227-235.
33. Unified Parkinson's disease rating scale (UPDRS). Available from: http://www.mdvu.org/library/ratingscales/pd/updrs.pdf. Accessed January 19, 2011.
34. Menza M, Marin H, Kaufman K. Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16(3):315-319.
35. Andrews D, Patrick R, Barchas J. The effects of 5-hydroxytryptophan and 5-hydroxytryptamine on dopamine synthesis and release in rat brain striatal synaptosomes. J Neurochem. 1978;30:465-470.
36. Awazi N. Guldberg H. On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum arch. Pharmacology. 1978;303:63-72.
37. Trachte G, Uncini T, Hinz M. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat. 2009;5:227-235.
38. Koepsell H, Schmitt B, Gorboulev V. Organic cation transporters. Physiol Biochem Pharmacol. 2003;150:36-90.